An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Double-blind Placebo Controlled Study With Extension to Assess the Safety and Efficacy of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Trial Profile

An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Double-blind Placebo Controlled Study With Extension to Assess the Safety and Efficacy of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs CDZ 173 (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Apr 2019 to 21 Feb 2019.
    • 02 May 2017 Planned primary completion date changed from 1 Apr 2019 to 22 Jan 2019.
    • 29 Apr 2016 Planned End Date changed from 1 Jul 2017 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top